Showing 1081-1090 of 2894 results for "".
Find Your Niche
https://practicaldermatology.com/topics/practice-management/find-your-niche-1/20268/Learn what you’re good at and what you have a passion for and then start channeling your career and education in that direction, Hilary Baldwin, MD recommends. She says finding an area of focus and expertise is a key to finding satisfaction and happiness at work.Toxic Attitudes Toward Skin Bleaching
https://practicaldermatology.com/conferences/aad-2021/toxic-attitudes-toward-skin-bleaching/19925/Unregulated ingredients intended for skin lightening and bleaching range from the toxic to the simply unproven. Seemal Desai, MD says dermatologists should educate patients about physician-recommended, well-studied treatments and the risks of unregulated products. He highlights increased attention tSARS-CoV-2 and the Skin: Inside the COVID-19 Dermatology Registry
https://practicaldermatology.com/conferences/aad-2021/sars-cov-2-and-the-skin-inside-the-covid-19-dermatology-registry/19921/From COVID Toes to COVID Arms, dermatologic manifestations of SARS-CoV-2 infection and COVID-19 vaccination abound. Esther Freeman, MD, PhD, Director of the COVID-19 Dermatology Registry provides an overview of findings and shares information about the relatively new vaccine registry.The Skin Cancer Foundation at 40
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-skin-cancer-foundation-at-40/19614/Skin Cancer Foundation president Deborah Sarnoff, MD talks about the Foundation's accomplishments, its current focus, and future goals. Founded in 1979, the foundation has helped educate the public on skin cancer risk and supports dermatologists in practice.Effective Communication: Achieve Results You Want
https://practicaldermatology.com/topics/practice-management/effective-communication-achieve-results-you-want/19593/Kalyani Marathe, MD describes the Path to Action plan that can help you improve your communication skills—whether you're presenting, consulting with colleagues, or talking to patients. She offers tips for assessing your skills and finding ways to change your approach when needed.Exploring the Complexities of Psoriasis
https://practicaldermatology.com/topics/psoriasis/exploring-the-complexities-of-psoriasis/18553/Biologic therapies developed over the last decade or more to treat psoriasis may do more than clear the skin. Researchers are investigating the effects of treatment on comorbid risks, and comparing treatment with older interventions. Jashin Wu, MD explains.My New Favorite Thing: Budget-free Consults
https://practicaldermatology.com/topics/practice-management/my-new-favorite-thing-budget-free-consults/19043/Don't let budget concerns limit the patient consult. Steve Yoelin, MD says that the patient evaluation and consult should focus on the patient's concerns and the physician's expertise about how to address those. Then the conversation can move toward devising a regimen that fits the patient's budgetDermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."Anti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.PsA-5T-Ds: A New Psoriatic Arthritis Assessment Tool
https://practicaldermatology.com/topics/psoriasis/psa-5t-ds-a-new-psoriatic-arthritis-assessment-tool/20227/The PsA 5-Thermometer Scale Domains (PsA-5T-Ds) measures patient-reported pain, fatigue, physical function, skin problems, and depression. Here, Philip Mease, MD, discusses the validity of this tool in three Phase 3 studies of guselkumab as well as the role it could play in practice.